HKEX Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
Apr
14
NOTICE OF ANNUAL GENERAL MEETING
Apr
09
INVESTIGATIONAL NEW DRUG NBL-015 GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
Apr
01
VOLUNTARY ANNOUNCEMENT - "AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
Mar
30
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF "DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)"
Mar
29
VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar
25
VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar
16
VOLUNTARY ANNOUNCEMENT - DUAL INHIBITOR JAK-SyK "SYHX1901" OBTAINS CLINICAL TRIAL APPROVAL
Mar
15
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020
Mar
10
VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSING AND COMMERCIALIZATION AGREEMENT
Mar
09
VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSING AND COMMERCIALIZATION AGREEMENT
Mar
09
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Mar
05
APPOINTMENT AND RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS
Mar
05
POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 5 MARCH 2021
Mar
04
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 December 2020
Mar
03
DATE OF BOARD MEETING
Feb
07
NOTICE OF 2021 FIRST EXTRAORDINARY GENERAL MEETING
Feb
01
PROPOSED ISSUE OF RMB SHARES UNDER SPECIFIC MANDATE PROPOSED AMENDMENTS TO ARTICLES OF ASSOCIATION
Jan
27
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Jan
27
APPOINTMENT AND RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHANGE OF BOARD COMMITTEE S
Jan
08
VOLUNTARY ANNOUNCEMENT - NBL-012 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2021 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer